source
- Verastem reports promising early results for KRAS G12D inhibitor in pancreatic and lung cancersVerastem Oncology has shifted its research toward a KRAS G12D inhibitor, VS-7375, and released early data from a phase 1/2 study involving more than 200 patients with advanced KRAS G12D-mutated sol…
- Zealand Pharma partners with Generate Biomedicines on multispecific obesity proteins in $1.2B dealZealand Pharma has agreed to pay Generate Biomedicines $30 million up front to start work on multispecific protein drug candidates aimed at obesity and other metabolic disorders. The agreement inc…